Emerging therapeutic options against filoviruses

Drugs of the Future

Volumn 37, Issue 5, 2012, Pages 343-351

  Reid, St P ^a   Shurtleff, A C ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antioxidants; Ebolavirus; Filoviruses; Marburgvirus; Small molecule inhibitors

Indexed keywords

3 DEAZAADENOSINE; 3 DEAZANEPLANOCIN; 3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; ANTIOXIDANT; ANTIVIRUS AGENT; AVI 6002; AVI 6003; CHLORIN E6; COMPOUND 3.0; COMPOUND 3.18; COMPOUND 3.47; COMPOUND 7; FGI 103; FGI 104; FGI 106; FILOVIRUS VACCINE; IMIPRAMINE; LIPOSOME; LJ 001; MORPHOLINO OLIGONUCLEOTIDE; NSC 62914; OXOCARBAZATE; PIPERAZINE; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; TETRAHYDROQUINOLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; BIOLOGICAL WARFARE AGENT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EBOLA VIRUS; EPIDEMIC; FILOVIRUS; FILOVIRUS INFECTION; GENE TARGETING; HUMAN; IMMUNOPATHOLOGY; LIPOSOMAL GENE DELIVERY SYSTEM; MARBURG VIRUS; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; RNA INTERFERENCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS PATHOGENESIS;

EID: 84952986156     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2012.037.05.1784684     Document Type: Review

References (118)

1. Miranda, M.E., Miranda, N.L. Reston ebolavirus in humans and animals in the Philippines: A review. J Infect Dis 2011, 204(Suppl. 3): S757-60.
2. Negredo, A., Palacios, G., Vázquez-Morón, S. et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 2011, 7(10): e1002304.
3. Towner, J.S., Sealy, T.K., Khristova, M.L. et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008, 4(11): e1000212.
4. Kuhn, J.H., Becker, S., Ebihara, H. et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010, 155(12): 2083-103.
5. Beniac, D.R., Melito, P.L., Devarennes, S.L. et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 2012, 7(1): e29608.
6. Bharat, T.A., Riches, J.D., Kolesnikova, L. et al. Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. PLoS Biol 2011, 9(11): e1001196.
7. Johnson, E., Jaax, N., White, J., Jahrling, P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995, 76(4): 227-36.
8. Kuhn, J.H. Filoviruses. A compendium of 40 years of epidemiological, clinical and laboratory studies. Arch Virol Suppl 2008, 20: 13-360.
9. Basler, C.F., Wang, X., Mühlberger, E. et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000, 97(22): 12289-94.
10. Cárdenas, W.B., Loo, Y.M., Gale, M. Jr. et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006, 80(11): 5168-78.
11. Chang, T.H., Kubota, T., Matsuoka, M., Jones, S., Bradfute, S.B., Bray, M., Ozato, K. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009, 5(6): e1000493.
12. Prins, K.C., Cardenas, W.B., Basler, C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009, 83(7): 3069-77.
13. Schumann, M., Gantke, T., Muhlberger, E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 2009, 83(17): 8993-7.
14. Gale, M. Jr., Katze, M.G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998, 78(1): 29-46. (Pubitemid 28178928)
15. Fabozzi, G., Nabel, C.S., Dolan, M.A., Sullivan, N.J. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol 2011, 85(6): 2512-23.
16. Haasnoot, J., de Vries, W., Geutjes, E.J., Prins, M., de Haan, P., Berkhout, B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 2007, 3(6): e86.
17. Reid, S.P., Leung, L.W., Hartman, A.L. et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006, 80(11): 5156-67.
18. Mateo, M., Reid, S.P., Leung, L.W., Basler, C.F., Volchkov, V.E. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol 2010, 84(2): 1169-75.
19. Reid, S.P., Valmas, C., Martinez, O., Sanchez, F.M., Basler, C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007, 81(24): 13469-77. (Pubitemid 350252964)
20. Shabman, R.S., Gulcicek, E.E., Stone, K.L., Basler, C.F. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin alpha1 and partially alters its nuclear import. J Infect Dis 2011, 204(Suppl. 3): S904-10.
21. Ebihara, H., Takada, A., Kobasa, D. et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006, 2(7): e73.
22. Subbotina, E., Dadaeva, A., Kachko, A., Chepurnov, A. Genetic factors of Ebola virus virulence in guinea pigs. Virus Res 2010, 153(1): 121-33.
23. Volchkov, V.E., Dadaeva, A., Kachko, A., Chepurnov, A. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000, 277(1): 147-55.
24. Mateo, M., Carbonnelle, C., Martinez, M.J. et al. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J Infect Dis 2011, 204(Suppl. 3): S1011-20.
25. Valmas, C., Grosch, M.N., Schumann, M. et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog 2010, 6(1): e1000721.
26. Valmas, C., Basler, C.F. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol 2011, 85(9): 4309-17.
27. Murray, P.J. The JAK-STAT signaling pathway: Input and output integration. J Immunol 2007, 178(5): 2623-9. (Pubitemid 46333135)
28. Kaletsky, R.L., Francica, G.R., Agrawal-Gamse, C., Bates, P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 2009, 106(8): 2886-91.
29. Sanchez, A., Trappier, S.G., Mahy, B.W., Peters, C.J., Nichol, S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996, 93(8): 3602-7. (Pubitemid 26125667)
30. Volchkova, V.A., Klenk, H.D., Volchkov, V.E. Delta-peptide is the carboxyterminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 1999, 265(1): 164-71. (Pubitemid 30012395)
31. Dolnik, O., Volchkova, V., Garten, W. et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 2004, 23(10): 2175-84. (Pubitemid 38737744)
32. Mehedi, M., Falzarano, D., Seebach, J., Hu, X., Carpenter, M.S., Schnittler, H.J., Feldmann, H. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 2011, 85(11): 5406-14.
33. Wahl-Jensen, V.M., Afanasieva, T.A., Seebach, J., Stroher, U., Feldmann, H., Schnittler, H.J. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005, 79(16): 10442-50. (Pubitemid 41098584)
34. Radoshitzky, S.R., Warfield, K.L., Chi, X. et al. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J Virol 2011, 85(17): 8502-13.
35. Chan, S.Y., Ma, M.C., Goldsmith, M.A. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 2000, 81(Pt. 9): 2155-9.
36. Simmons, G., Wool-Lewis, R.J., Baribaud, F., Netter, R.C., Bates, P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002, 76(5): 2518-28. (Pubitemid 34150720)
37. Sullivan, N.J., Peterson, M., Yang, Z.Y., Kong, W.P., Duckers, H., Nabel, E., Nabel, G.J. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 2005, 79(1): 547-53. (Pubitemid 39648407)
38. Yang, Z.Y., Duckers, H.J., Sullivan, N.J., Sanchez, A., Nabel, E.G., Nabel, G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000, 6(8): 886-9. (Pubitemid 30644746)
39. Alazard-Dany, N., Volchkova, V., Reynard, O. et al. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 2006, 87(Pt. 5): 1247-57.
40. Reynard, O., Borowiak, M., Volchkova, V.A., Delpeut, S., Mateo, M., Volchkov, V.E. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 2009, 83(18): 9596-601.
41. Jaax, N., Jahrling, P., Geisbert, T. et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995, 346(8991-8992): 1669-71. (Pubitemid 26003325)
42. Geisbert, T.W., Young, H.A., Jahrling, P.B., Davis, K.J., Larsen, T., Kagan, E., Hensley, L.E. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003, 163(6): 2371-82. (Pubitemid 37474154)
43. Ryabchikova, E.I., Kolesnikova, L.V., Luchko, S.V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999, 179(Suppl. 1): S199-202. (Pubitemid 29091403)
44. Bosio, C.M., Aman, M.J., Grogan, C. et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003, 188(11): 1630-8. (Pubitemid 38010672)
45. Leung, L.W., Martinez, O., Reynard, O., Volchkov, V.E., Basler, C.F. Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis 2011, 204(Suppl. 3): S973-7.
46. Colonna, M., Trinchieri, G., Liu, Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004, 5(12): 1219-26. (Pubitemid 41057736)
47. Leung, L.W., Park, M.S., Martinez, O., Valmas, C., Lopez, C.B., Basler, C.F. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol 2011, 89(7): 792-802.
48. Feldmann, H., Bugany, H., Mahner, F., Klenk, H.D., Drenckhahn, D., Schnittler, H.J. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996, 70(4): 2208-14. (Pubitemid 26087581)
49. Stroher, U., West, E., Bugany, H., Klenk, H.D., Schnittler, H.J., Feldmann, H. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001, 75(22): 11025-33. (Pubitemid 33031570)
50. Baize, S., Leroy, E.M., Georges-Courbot, M.C. et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999, 5(4): 423-6. (Pubitemid 29180581)
51. Bradfute, S.B., Swanson, P.E., Smith, M.A., Watanabe, E., McDunn, J.E., Hotchkiss, R.S., Bavari, S. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol 2010, 184(1): 327-35.
52. Geisbert, T.W., Hensley, L.E., Gibb, T.R., Steele, K.E., Jaax, N.K., Jahrling, P.B. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000, 80(2): 171-86. (Pubitemid 30120970)
53. Hoenen, T., Groseth, A., Falzarano, D., Feldmann, H. Ebola virus: Unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006, 12(5): 206-15. (Pubitemid 43728410)
54. Mahanty, S., Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004, 4(8): 487-98. (Pubitemid 39077918)
55. Liu, G., Wong-Staal, F., Li, Q.X. Development of new RNAi therapeutics. Histol Histopathol 2007, 22(2): 211-7. (Pubitemid 46117107)
56. Davidson, B.L., McCray, P.B. Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12(5): 329-40.
57. Haasnoot, J., Westerhout, E.M., Berkhout, B. RNA interference against viruses: Strike and counterstrike. Nat Biotechnol 2007, 25(12): 1435-43. (Pubitemid 350233142)
58. Geisbert, T.W., Hensley, L.E., Kagan, E. et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193(12): 1650-7. (Pubitemid 43839469)
59. Geisbert, T.W., Lee, A.C., Robbins, M. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 2010, 375(9729): 1896-905.
60. Fowler, T., Bamberg, S., Moller, P., Klenk, H.D., Meyer, T.F., Becker, S., Rudel, T. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005, 86(Pt. 4): 1181-8. (Pubitemid 40485676)
61. Shurtleff, A.C., Warren, T., Bavari, S. Nonhuman primates as models for the discovery and development of ebolavirus therapeutics. Expert Opin Drug Discov 2011, 6(3): 233-50.
62. Spurgers, K.B., Sharkey, C.M., Warfield, K.L., Bavari, S. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008, 78(1): 26-36.
63. Summerton, J.E., Morpholino, siRNA, and S-DNA compared: Impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 2007, 7(7): 651-60. (Pubitemid 46681848)
64. Jason, T.L., Koropatnick, J., Berg, R.W. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004, 201(1): 66-83. (Pubitemid 39446327)
65. Dias, N., Stein, C.A. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 2002, 1(5): 347-55.
66. Enterlein, S., Warfield, K.L., Swenson, D.L. et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006, 50(3): 984-93. (Pubitemid 43327804)
67. Moulton, H.M., Nelson, M.H., Hatlevig, S.A., Reddy, M.T., Iversen, P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004, 15(2): 290-9. (Pubitemid 38365188)
68. Warfield, K.L., Swenson, D.L., Olinger, G.G. et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006, 2(1): e1.
69. Swenson, D.L., Warfield, K.L., Warren, T.K. et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009, 53(5): 2089-99.
70. Warren, T.K., Warfield, K.L., Wells, J. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010, 16(9): 991-4.
71. Aman, M.J., Kinch, M.S., Warfield, K. et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009, 83(3): 245-51.
72. Guo, H., Pan, X., Mao, R. et al. Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother 2011, 55(2): 478-86.
73. Kinch, M.S., Yunus, A.S., Lear, C. et al. FGI-104: A broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009, 1(1): 87-98.
74. Warren, T.K., Warfield, K.L., Wells, J. et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010, 54(5): 2152-9
75. Opsenica, I., Burnett, J.C., Gussio, R. et al. A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem 2011, 54(5): 1157-69.
76. Basu, A., Li, B., Mills, D.M. et al. Identification of a small-molecule entry inhibitor for filoviruses. J Virol 2011, 85(7): 3106-19.
77. Shah, P.P., Wang, T., Kaletsky, R.L. et al. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol 2010, 78(2): 319-24.
78. Wolf, M.C., Freiberg, A.N., Zhang, T. et al., A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010, 107(7): 3157-62.
79. Liu, T., Weng, Z., Dong, X., Hu, Y. Recent advances in the development of small-molecule CCR5 inhibitors for HIV. Mini Rev Med Chem 2010, 10(13): 1277-92.
80. Becker, S., Spiess, M., Klenk, H.D. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 1995, 76(Pt. 2): 393-9.
81. Takada, A., Watanabe, S., Ito, H., Okazaki, K., Kida, H., Kawaoka, Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: Implication for virus entry. Virology 2000, 278(1): 20-6. (Pubitemid 32002589)
82. Chan, S.Y., Empig, C.J., Welte, F.J., Speck, R.F., Schmaljohn, A., Kreisberg, J.F., Goldsmith, M.A. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 2001, 106(1): 117-26. (Pubitemid 32709963)
83. Alvarez, C.P., Lasala, F., Carrillo, J., Muñiz, O., Corbi, A.L., Delgado, R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002, 76(13): 6841-4. (Pubitemid 34633551)
84. Shimojima, M., Takada, A., Ebihara, H. et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 2006, 80(20): 10109-16. (Pubitemid 44522604)
85. Kondratowicz, A.S., Lennemann, N.J., Sinn, P.L. et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 2011, 108(20): 8426-31.
86. Carette, J.E., Raaben, M., Wong, A.C. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011, 477(7364): 340-3.
87. Côté, M., Misasi, J., Ren, T. et al. Small molecule inhibitors reveal Niemann- Pick C1 is essential for Ebola virus infection. Nature 2011, 477(7364): 344-8.
88. Carstea, E.D., Morris, J.A., Coleman, K.G. et al. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science 1997, 277(5323): 228-31. (Pubitemid 27446076)
89. Lloyd-Evans, E., Morgan, A.J., He, X. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 2008, 14(11): 1247-55.
90. Tang, Y., Leao, I.C., Coleman, E.M., Broughton, R.S., Hildreth, J.E. Deficiency of Niemann-Pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartments. J Virol 2009, 83(16): 7982-95.
91. Geisbert, T.W., Daddario-DiCaprio, K.M., Geisbert, J.B. et al. Marburg virus Angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007, 196(Suppl. 2): S372-81. (Pubitemid 351417284)
92. Geisbert, T.W., Hensley, L.E., Jarhling, P.B. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 2003, 362(9400): 1953-8. (Pubitemid 37548417)
93. Bray, M., Driscoll, J., Huggins, J.W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000, 45(2): 135-47. (Pubitemid 30156782)
94. Hensley, L.E., Stevens, E.L., Yan, S.B. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(Suppl. 2): S390-9. (Pubitemid 351417286)
95. Huggins, J., Zhang, Z.X., Bray, M. Antiviral drug therapy of filovirus infections: S-Adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999, 179(Suppl. 1): S240-7. (Pubitemid 29091408)
96. Geisbert, T.W., Young, H.A., Jahrling, P.B., Davis, K.J., Kagan, E., Hensley, L.E. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003, 188(11): 1618-29. (Pubitemid 38010671)
97. Macias, W.L., Nelson, D.R. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32(5, Suppl.): S223-8.
98. Shorr, A.F., Bernard, G.R., Dhainaut, J.F., Russell, J.R., Macias, W.L., Nelson, D.R., Sundin, D.P. Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006, 10(3): R92.
99. Teijaro, J.R., Walsh, K.B., Cahalan, S. et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011, 146(6): 980-91.
100. Hensley, L.E., Geisbert, T.W. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 2005, 94(2): 254-61. (Pubitemid 41122478)
101. Harcourt, B.H., Sanchez, A., Offermann, M.K. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 1998, 252(1): 179-88. (Pubitemid 28564143)
102. Schnittler, H.J., Feldmann, H. Viral hemorrhagic fever - A vascular disease? Thromb Haemost 2003, 89(6): 967-72. (Pubitemid 36798147)
103. Schnittler, H.J., Mahner, F., Drenckhahn, D., Klenk, H.D., Feldmann, H. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. J Clin Invest 1993, 91(4): 1301-9. (Pubitemid 23127325)
104. Hensley, L.E., Young, H.A., Jahrling, P.B., Geisbert, T.W. Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002, 80(3): 169-79. (Pubitemid 34136004)
105. Halliwell, B., Gutteridge, J.M., Cross, C.E. Free radicals, antioxidants, and human disease: Where are we now? J Lab Clin Med 1992, 119(6): 598-620.
106. Bove, P.F., van der Vliet, A. Nitric oxide and reactive nitrogen species in airway epithelial signaling and inflammation. Free Radic Biol Med 2006, 41(4): 515-27. (Pubitemid 44080515)
107. Acharya, A., Das, I., Chandhok, D., Saha, T. Redox regulation in cancer: A double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010, 3(1): 23-34.
108. Mishra, M.K., Ghosh, D., Duseja, R., Basu, A. Antioxidant potential of minocycline in Japanese encephalitis virus infection in murine neuroblastoma cells: Correlation with membrane fluidity and cell death. Neurochem Int 2009, 54(7): 464-70.
109. Patten, D.A., Germain, M., Kelly, M.A., Slack, R.S. Reactive oxygen species: Stuck in the middle of neurodegeneration. J Alzheimers Dis 2010, 20(Suppl. 2): S357-67.
110. Schwarz, K.B. Oxidative stress during viral infection: A review. Free Radic Biol Med 1996, 21(5): 641-9. (Pubitemid 26331094)
111. Andersen, J.K. Oxidative stress in neurodegeneration: Cause or consequence? Nat Med 2004, 10(Suppl.): S18-25. (Pubitemid 38901863)
112. Grossman, E. Does increased oxidative stress cause hypertension? Diabetes Care 2008,31(Suppl. 2): S185-9.
113. Thimmulappa, R.K., Lee, H., Rangasamy, T., Reddy, S.P., Yamamoto, M., Kensler, T.W., Biswal, S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116(4): 984-95.
114. Panchal, R.G., Reid, S.P., Tran, J.P. et al. Identification of an antioxidant small molecule with broad-spectrum antiviral activity. Antiviral Res 2011, 93(1): 23-9.
115. Moreno-Otero, R., Trapero-Marugan, M. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol 2010, 16(15): 1937-8.
116. Uchide, N., Toyoda, H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules 2011, 16(3): 2032-52.
117. Bradfute, S.B., Dye, J.M. Jr., Bavari, S. Filovirus vaccines. Hum Vaccin 2011, 7(6): 701-11.
118. Falzarano, D., Geisbert, T.W., Feldmann, H. Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 2011, 10(1): 63-77.